Making antibodies by phage display technology
Abstract
Antibody fragments of predetermined binding specificity have recently been constructed from repertoires of antibody V genes, bypassing hybridoma technology and even immunization. The V gene repertoires are harvested from populations of lymphocytes, or assembled in vitro, and cloned for display of associated heavy and light chain variable domains on the surface of filamentous bacteriophage. Rare phage are selected from the repertoire by binding to antigen; soluble antibody fragments are expressed from infected bacteria; and the affinity of binding of selected antibodies is improved by mutation. The process mimics immune selection, and antibodies with many different binding specificities have been isolated from the same phage repertoire. Thus human antibody fragments have been isolated with specificities against both foreign and self antigens, including haptens, carbohydrates, secreted and cell surface proteins, viral coat proteins, and intracellular antigens from the lumen of the endoplasmic reticulum and the nucleus. Such antibodies have potential as reagents for research and in therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recombinant primaries (anti-βIII-tubulin NPC2-5) leverage phage display technology from synthetic libraries, eliminating immunization entirely while providing CHO/HEK scalability and batch consistency.
“Recombinant primaries (anti-βIII-tubulin NPC2-5) leverage phage display technology from synthetic libraries, eliminating immunization entirely while providing CHO/HEK scalability and batch consistency (Winter et al., 1994).”
From Challenges and solutions in transitioning to animal-free standards: a comprehensive analysis of components in human cell-based developmental neurotoxicity assays (2026) · cites this paper as Winter et al., 1994
Cited by
Sorted by citations
Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., & Virnekäs, B. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3444 · Cited by 728 · see citing works
The fibronectin type III domain as a scaffold for novel binding proteins
Koide, A., Bailey, C. W., Huang, X., & Koide, S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2238 · Cited by 585 · see citing works
The CamSol method of rational design of protein mutants with enhanced solubility
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.026 · Cited by 494 · see citing works
RosettaAntibodyDesign (RAbD): a general framework for computational antibody design
Adolf-Bryfogle, J., Kalyuzhniy, O., Kubitz, M., Weitzner, B. D., Hu, X., Adachi, Y., Schief, W. R., & Dunbrack, R. L. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006112 · Cited by 227 · see citing works
<scp>AB</scp> ‐Bind: Antibody binding mutational database for computational affinity predictions
Sirin, S., Apgar, J. R., Bennett, E. M., & Keating, A. E. (2016) · Protein Science · doi:10.1002/pro.2829 · Cited by 179 · see citing works
Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?
Dimitrov, D. S., & Marks, J. D. (2009) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-554-1_1 · Cited by 132 · see citing works
Analyzing the ‘Degree of Humanness’ of antibody sequences
Abhinandan, K. R., & Martin, A. C. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.100 · Cited by 99 · see citing works
Human Monoclonal Antibodies: The Benefits of Humanization
Waldmann, H. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8958-4_1 · Cited by 80 · see citing works
Free energy perturbation calculations of the thermodynamics of protein side-chain mutations
Steinbrecher, T., Abel, R., Clark, A., & Friesner, R. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.002 · Cited by 46 · see citing works
Development of scoring functions for antibody sequence assessment and optimization
Seeliger, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076909 · Cited by 24 · see citing works
In vitro affinity maturation of antibody against membrane-bound GPCR molecules
Wang, J., An, L., Zhao, Y., Zhang, C., Li, S., Ye, C., Jing, S., & Hang, H. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10030-x · Cited by 11 · see citing works
Spänle, J. V., Haiber, L. M., & Seeger, B. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1800157 · Cited by 1 · see citing works
- Authors
- Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R.
- Affiliations
- MRC Centre for Protein Engineering, Cambridge, UK
- Cambridge Antibody Technology, The Science Park, Melbourn, Cambridgeshire
- Venue
- Annual Review of Immunology
- Publisher
- Annual Reviews
- Published
- 1994-04
- Volume
- 12
- Issue
- 1
- Pages
- 433-455
- ISSN
- 0732-0582
- 1545-3278
- Cited by
- 1,294
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
